A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections

Ceran, Nurgül; Mert, Duygu; Kocdogan, Funda Yuksel; Erdem, İlknur; Adalati, Rıza; Özyürek, Seyfi; Göktaş, Paşa

doi:10.1007/s10156-010-0079-z

Cited by 47 publications

(33 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three additional RCTs evaluating the effectiveness and safety of fosfomycin for lower UTIs in females have been published since then ( Table 4). All of them reported that fosfomycin trometamol was as affective as comparator antibiotics, regardless of the patients' hormonal or pregnancy status (224)(225)(226).…”

Section: Urinary Tract Infectionsmentioning

confidence: 99%

Fosfomycin

et al. 2016

View full text Add to dashboard Cite

SUMMARYThe treatment of bacterial infections suffers from two major problems: spread of multidrug-resistant (MDR) or extensively drug-resistant (XDR) pathogens and lack of development of new antibiotics active against such MDR and XDR bacteria. As a result, physicians have turned to older antibiotics, such as polymyxins, tetracyclines, and aminoglycosides. Lately, due to development of resistance to these agents, fosfomycin has gained attention, as it has remained active against both Gram-positive and Gram-negative MDR and XDR bacteria. New data of higher quality have become available, and several issues were clarified further. In this review, we summarize the available fosfomycin data regarding pharmacokinetic and pharmacodynamic properties, thein vitroactivity against susceptible and antibiotic-resistant bacteria, mechanisms of resistance and development of resistance during treatment, synergy and antagonism with other antibiotics, clinical effectiveness, and adverse events. Issues that need to be studied further are also discussed.

show abstract

Section: Urinary Tract Infectionsmentioning

confidence: 99%

Fosfomycin

et al. 2016

View full text Add to dashboard Cite

show abstract

“…[17] Üç günlük CP tedavisi kullandı-ğımız çalışmamızda CP'ye karşı daha yüksek bir yan etki oranı görüldü. FT'ye bağlı yan etki insidansı ile ilgili de literatür-de %6.7 ile %26 arsında değişen oranlar bildirilmiştir.…”

Section: Discussionunclassified

Comparison of Fosfomysin Trometamol and Ciprofloxacin in Uncomplicated Urinary Tract Infections

et al. 2011

View full text Add to dashboard Cite

SUMMARY Objectives Acute urinary tract infection (UTI) is one of the most common infections requiring empirical antibiotic therapy. Selection of efficient and safe antimicrobial agent is important in the emergency department (ED). The aim of this study is to compare the microbiological and clinical efficiency of single-dose fosfomycin trometamol (FT) therapy with a 3-day course of ciprofloxacin (CP) for the treatment of uncomplicated UTI. Methods ÖZET AmaçAkut komplike olmayan alt üriner sistem enfeksiyonları en sık ampirik antibiyotik reçete edilen enfeksiyonlardır. Acil serviste (AS) gü-venilir ve etkin bir antimikrobiyal ajan seçimi önemlidir. Bu çalış-manın amacı, acil servise başvuran akut komplike olmayan üriner sistem enfeksiyonu olan hastalarda tek doz fosfomisin trometorol (FT) ve 3 gün siprofloksasinin (CP) klinik ve mikribiyolojik etkinliği-nin karşılaştırılmasıdır. Gereç ve YöntemBu randomize, tek kör, prospektif çalışmada AS'ye semptomları son 72 saat içinde başlayan, dizüri, idrara sıkışma hissi ve sık idrara gitme şikayeti ile başvuran 18-65 yaş kadın hastalar değerlen-dirildi. Bir grup hasta tek doz FT, diğer grup 3 günlük CP tedavisi aldı. İlk idrar kültürlerinde üreme olan hastalar çalışma grubunu oluşturdu. Tedaviden sonraki 7.-10. günlerde klinik ve mikrobiyolojik kür değerlendirildi. Tedavi rejimlerinin etkinliği ki-kare testi ile karşılaştırıldı. BulgularÇalışmadaki 81 kadının yaş ortalaması 30±2 idi. FT grubunda 40, CP grubunda 41 hasta vardı. En sık izole edilen üropatojen 50 ör-nekte bulunan E. coli idi (%61.3). Klinik olarak iyileşme CP grubunda 38 (%93), FT grubunda 38 (%96) hastada saptandı (χ²: 0,347, df: 1, p=0.275). Bakteriyolojik eradikasyon CP grubundaki hastaların 27 (%65,8), FT grubundaki hastaların 32'sinde (%80) elde edildi (χ²: 0.1591, df: 1, p=0.207). FT grubunda yalnızca 3 hastada (%7.5) pirozis görülürken CP grubunda 4 hastada (%10) pirozis, 5 hastada (%12) bulantı görüldü. SonuçKomplike olmayan üriner sistem enfeksiyonu olan kadın hastalarda tek doz FT ampirik antibiyotik olarak CP kadar etkin ve güvenlidir.Anahtar sözcükler: Ampirik tedavi; fosfomisin trometamol; idrar yolu infeksiyonu; siprofloksasin. 104

show abstract

“…However, a recent meta-analysis of 27 trials found no difference in efficacy between fosfomycin and other antibiotics for the treatment of cystitis and found that fosfomycin was associated with significantly fewer adverse reactions in pregnant women [31]. In addition, in a recent randomized single-blinded study, single dose fosfomycin at 3 g was as effective as ciprofloxacin, at 500 mg twice a day for 5 days, in the treatment of acute uncomplicated cistitis [32]. demonstrated that fosfomycin is active against vancomycin-resistant Staphylococcus aureus, and ESBL-producing Gram-negative rods [1,[23][24][25].…”

Section: Management Of Acute Uncomplicated Cystitismentioning

confidence: 99%